Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 5/20 | 0.81 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.81 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.81 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.81 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.81 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.81 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.81 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.81 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.81 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.81 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.81 |
| ▸ | ABL1 | P00519 | 12/20 | 0.79 |
| ▸ | SRC | P12931 | 9/20 | 0.79 |
| ▸ | LCK | P06239 | 5/20 | 0.79 |
| ▸ | EGFR | P00533 | 3/20 | 0.79 |
| ▸ | FYN | P06241 | 3/20 | 0.79 |
| ▸ | YES1 | P07947 | 3/20 | 0.79 |
| ▸ | LYN | P07948 | 3/20 | 0.79 |
| ▸ | HCK | P08631 | 3/20 | 0.79 |
| ▸ | KIT | P10721 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22452260 | 0.93 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14067014 | 0.93 | HDAC3 (0.82) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1147164 | 0.92 | HDAC3 (0.82) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL22604972 | 0.91 | HDAC3 (0.79) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL29816897 | 0.91 | HDAC3 (0.79) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13637397 | 0.91 | HDAC1 (0.68) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL29750253 | 0.91 | HDAC3 (0.86) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1704971 | 0.91 | HDAC3 (0.86) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14416600 | 0.91 | HDAC3 (0.86) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19362612 | 0.91 | ABL1 (0.85) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| US-9169244-B2 | Tyrosine kinase inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140128410-A1 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8426419-B2 | Tyrosine kinase inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110178095-A1 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2011-07-21 | — | — | US | disclosed |
| US-7888361-B2 | anticancer; inhibits both BCR-ABL and histone deacetylase activity; N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-(hydroxyamino)-2-oxoethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide | CURIS, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| US-7622473-B2 | 'N-(2-chloro-6-methylphenyl)-2-[[(6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622473-B2 | 'N-(2-chloro-6-methylphenyl)-2-[[(6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622473-B2 | 'N-(2-chloro-6-methylphenyl)-2-[[(6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| US-20080125440-A1 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033746-A2 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007106879-A2 | PROCESS FOR PREPARING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO]-5-THIAZOLECARBOXAMIDE AND RELATED METABOLITES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007106879-A2 | PROCESS FOR PREPARING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO]-5-THIAZOLECARBOXAMIDE AND RELATED METABOLITES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070219370-A1 | PROCESS FOR PREPARING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO] -5-THIAZOLECARBOXAMIDE AND RELATED METABOLITES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-20 | — | — | US | disclosed |
| US-20070219370-A1 | PROCESS FOR PREPARING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO] -5-THIAZOLECARBOXAMIDE AND RELATED METABOLITES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-20 | — | — | US | disclosed |
| US-20070219370-A1 | PROCESS FOR PREPARING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO] -5-THIAZOLECARBOXAMIDE AND RELATED METABOLITES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-20 | — | — | US | disclosed |
| US-20060211705-A1 | 'N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219370-A1 | PROCESS FOR PREPARING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO] -5-THIAZOLECARBOXAMIDE AND RELATED METABOLITES THEREOF | UGT1A6, PAH, CYP2B6 | HDAC3 921/4885HDAC4 982/4885HDAC1 1279/4885 |
| US-20110178095-A1 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | LCK, ABL1, SRC | HDAC3 55/4885HDAC4 26/4885HDAC1 5/4885 |
| US-20060211705-A1 | 'N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites | IL2, TPMT, HNMT | HDAC3 162/4885HDAC4 370/4885HDAC1 278/4885 |
| US-20140128410-A1 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | LCK, ABL1, SRC | HDAC3 55/4885HDAC4 26/4885HDAC1 5/4885 |
| US-20080125440-A1 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | LCK, ABL1, SRC | HDAC3 55/4885HDAC4 26/4885HDAC1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.